Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BLINATUMOMAB Cause Staphylococcal infection? 34 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 34 reports of Staphylococcal infection have been filed in association with BLINATUMOMAB (BLINCYTO). This represents 0.4% of all adverse event reports for BLINATUMOMAB.

34
Reports of Staphylococcal infection with BLINATUMOMAB
0.4%
of all BLINATUMOMAB reports
8
Deaths
20
Hospitalizations

How Dangerous Is Staphylococcal infection From BLINATUMOMAB?

Of the 34 reports, 8 (23.5%) resulted in death, 20 (58.8%) required hospitalization, and 1 (2.9%) were considered life-threatening.

Is Staphylococcal infection Listed in the Official Label?

Yes, Staphylococcal infection is listed as a known adverse reaction in the official FDA drug label for BLINATUMOMAB.

What Other Side Effects Does BLINATUMOMAB Cause?

Pyrexia (1,064) Acute lymphocytic leukaemia recurrent (977) Cytokine release syndrome (952) Off label use (590) Death (588) Neurotoxicity (530) Drug ineffective (345) Headache (335) Neutropenia (265) Febrile neutropenia (262)

What Other Drugs Cause Staphylococcal infection?

ADALIMUMAB (1,727) METHOTREXATE (932) PREDNISONE (914) ETANERCEPT (850) TACROLIMUS (777) MYCOPHENOLATE MOFETIL (677) CYCLOPHOSPHAMIDE (625) RITUXIMAB (582) INFLIXIMAB (561) SECUKINUMAB (525)

Which BLINATUMOMAB Alternatives Have Lower Staphylococcal infection Risk?

BLINATUMOMAB vs BLONANSERIN BLINATUMOMAB vs --BLOOD-COAGULATION FACTOR VIII FUSION PROTEIN WITH IMMUNOGLOBULIN G1 , ,-BIS WITH IMMUNOGLOBULIN G1 BLINATUMOMAB vs BOCEPREVIR BLINATUMOMAB vs BOCOCIZUMAB BLINATUMOMAB vs BONIVA

Related Pages

BLINATUMOMAB Full Profile All Staphylococcal infection Reports All Drugs Causing Staphylococcal infection BLINATUMOMAB Demographics